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Background: Reduced cerebral blood flow and microvascular abnormalities have been suggested as the 
vascular pathogenesis of Alzheimer’s disease (AD). Transcranial Doppler sonography (TCD) can be used as a non-
invasive method for measuring cerebral vasomotor reactivity (VMR) which represent the capability of arterioles 
to dilate and constrict in order to maintain cerebral blood flow.
Objective: The objective of this study was to determine whether VMR is decreased in AD patients.
Methods: Seventeen consecutive patients who met NINDS-ADRDA criteria for AD, and 17 age- and sex- 
matched controls were included in this study. MRI and MRA were performed for the grading of white-matter lesions. 
Patients with cerebral infarct or stenosis of the middle cerebral artery (MCA) were excluded. The fixed TCD probe 
was used to monitor the mean flow velocity (MFV) in the MCA. A 6-L rebreathing bag was applied to patients for 
at least 5 minutes to elevate the CO2 concentration, which was continuously monitored with a capnometer. VMR was 
calculated as the percentage change in the MFV.
Results: Baseline characteristics - including cerebrovascular risk factors, grades of white-matter lesions, baseline 
MFV, and pulsatility index - did not differ between the two groups. Mini-Mental State Examination score was 
significantly low in AD group (20.5 vs. 27.5, p<0.05). VMR was significantly reduced in AD group both in the right- 
side (24.5% vs. 36.6%, p<0.05) and left-side (20.7% vs. 34.1%, p<0.05) MCAs.
Conclusions: Our finding that VMR is reduced in AD may be suggestive of underlying microangiopathic 
mechanism in AD patients. Future studies should check the validity of these experimental and hypothesis-generating 
pilot results.
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INTRODUCTION
Several epidemiological
1–4 and neuroimaging
5–7  studies 
performed during the last 10have provided evidence 
supporting the vascular pathogenesis of Alzheimer’s 
disease (AD). These studies have suggested that vascular 
risk factors directly reduce cerebral perfusion to a 
critical level of dysfunction, enhancing neuronal 
death in AD.
8,9 A recent population-based study using 
transcranial Doppler sonography (TCD) strongly supports 
this hypothesis by demonstrating that cerebral hypoper-
fusion precedes and possibly contributes to the onset of 
clinical dementia.
10 Another study has suggested that 
cerebral vasomotor reactivity (VMR) is a significant 
predictor of cognitive decline in AD patients.
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VMR refers to the capability to dilate or constrict 
cerebral arterioles in response to metabolic stimuli, such 
as CO2 or acetazolamide, which may be decreased in 
large-vessel occlusive disease or small-vessel micro-
angiopathy.
12 However, VMR has rarely been studied in 
AD patients, and it has not been clarified whether VMR 
is lower in AD patients than in nondemented subjects. 
Using a TCD rebreathing method, we investigated 
differences in VMR between AD patients and control 
subjects, which may be related to the vascular patho-
genesis of AD.
SUBJECTS AND METHODS
1. Subject inclusion and study design
Dementia patients aged from 55 to 80 years who met 
the NINDS-ADRDA criteria for AD were included in 
this study.
13 Age- and sex-matched control subjects 
without dementia were chosen from those who had 
visited the neurology clinic or health promotion center in 
Seoul National University Boramae Hospital. The 
Mini-Mental State Examination (MMSE), MRI, and 
MRA were applied to all subjects. Subjects who showed 
territorial infarcts, multiple lacunes, stenosis of the 
middle cerebral artery (MCA), or bilateral suboptimal 
temporal window were excluded. Because VMR can be 
affected by certain drugs such as statins
14 and angio-
tensin-converting enzyme inhibitors,
15 those using such 
drugs were also excluded. All subjects gave their informed 
consent. 
Changes in white-matter lesion severity in MRI were 
quantified used the Rotterdam Scan Study (RSS) scale,
16 
which separately scores the periventricular regions (peri-
ventricular score range: 0 to 9) and the volume of 
subcortical white-matter lesions (subcortical score range: 
0 to 29.5 mL).
2. TCD assessment and measurement of VMR
With the subject in a supine position, the TCD probe 
was used in a fixed position to monitor the mean flow 
velocity (MFV) in the MCA. A rebreathing method was 
adopted for elevating the CO2 concentration. A 6-L 
rebreathing bag with several pores was applied to 
patients via a facial mask for at least 5 minutes, and the 
CO2 concentration was continuously monitored with a 
capnometer. Subjects with inadequate CO2 retention (≤
45 mmHg) were excluded from the analysis. Baseline 
blood pressure, bilateral MFV, and pulsatility index (PI) 
were obtained, and MFV was continuously monitored 
and digitally recorded for later off-line analysis. VMR 
was calculated as the percentage change in the MFV 
according to VMR = (MFVhypercapnia–MFVnormocapnia)100/ 
MFVnormocapnia). Validation of this method and normal 
reference values have been presented previously.
17
3. Statistical analysis
Student’s  t-test was used for intergroup comparisons 
of continuous values, and the chi-square test was used 
for comparisons of categorical variables. The corre-
lations of VMR with the MMSE score and the grade of 
white-matter lesions were analyzed by bivariate 
correlation analysis. A probability value of p<0.05 was 
considered significant. All data are presented as mean±SD 
values.
RESULTS
Seventeen AD patients and 17 control subjects were 
recruited (age 67.1±5.9 years, range 55 to 78 years; 7 
males and 10 females per group). The MMSE score was 
significantly lower in AD patients than the control 
subjects (22.1±4.9 vs. 28.7±0.6, p=0.042). Other baseline 
characteristics - including cerebrovascular risk factors, 
medications, and grades of white-matter lesions - did not 
differ significantly between the two groups, as summa-
rized in Table 1.
Four and one AD patients showed suboptimal 
temporal windows on the right and left sides, respec-
tively. Therefore, we also excluded the corresponding 
TCD values of the matched control subjects from the 
analysis. The baseline MFV and PI also did not differ 
between the AD patients and the control subjects. 
However, VMR was significantly decreased in AD Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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Table 1. Baseline characteristics and VMR
 Control  (n=17) AD (n=17) p values
Male : Female 7 : 10 7 : 10 1.000
Mean Age - years 67.1±5.9 67.1±5.9 1.000
Mini Mental State Examination 28.7±0.6 22.1±4.9 0.042
Medical history - no. (%)
Hypertension 4 (23.5) 5 (29.4) 0.697
Diabetes mellitus 0 (0) 0 (0) -
Current smoking 1 (5.9) 2 (11.8) 0.545
Hyperlipidemia 3 (17.6) 3 (17.6) 1.000
Coronary artery disease 0 (0) 0 (0) -
Current medication - no. (%)
β-blockers 2 (11.8) 2 (11.8) 1.000
Calcium channel blockers   1 (5.9) 2 (11.8) 0.545
ACE inhibitors 1 (5.9) 1 (5.9) 1.000
Statins 3 (17.6) 3 (17.6) 1.000
Rotterdam Scan Study scale of MRI
Subcortical white matter lesion 1.3±0.6 1.7±1.1 0.259
Periventricular white matter lesion 0.6±1.3 1.5±1.8 0.180
Optimal temporal windows
Right MCA - no. 13 (adjusted) 13 -
Left MCA - no. 16 (adjusted) 16 -
Baseline mean flow velocity - cm/s  
Right 55.1±12.9 56.1±14.2 0.873
Left 57.7±15.4 56.3±12.2 0.768
Baseline pulsatility index  
Right 0.90±0.16 0.94±0.22 0.584
Left 0.88±0.12 0.92±0.18 0.386
Mean SBP / DBP - mmHg  
Normocapnia 129±22 / 80±10 130±17 / 77±8 0.876 / 0.190
Hypercapnia 151±23 / 89±10 151±20 / 84±8 0.927 / 0.056
Peak CO2 concentration - mmHg 51.5±2.4 51.1±2.3 0.643
While baseline MFV values did not differ between the two groups, VMR was lower in the AD group than in the control 
group. Statistical significances (p values) were tested by Student’s t-test for continuous values, and by the chi-square test 
for categorical variables.
ACE; angiotensin-converting enzyme, DBP; diastolic blood pressure, SBP; systolic blood pressure
patients in both the right- and left-side MCAs (Fig. 1): 
57.7±22.2 and 36.8±26.0 in control subjects and AD 
patients, respectively, on the right side (p=0.037); and 
58.7±21.1 and 37.2±22.7 on the left side (p=0.014). 
VMR was linearly correlated on the right and left sides 
(Pearson’s correlation coefficient=0.883, p=0.001). 
VMR and MMSE scores of AD patients were not 
significantly correlated either in the right-side (Pearson’s 
correlation coefficient=0.264, p=0.324) or left-side 
(Pearson’s correlation coefficient=0.095, p=0.758) MCA 
(Fig. 2). VMR of AD patients was not correlated with 
either the volume of subcortical white-matter lesions 
or the grade of periventricular white-matter lesions 
(all p >0.05).
DISCUSSION
Whether AD is a pure neurodegenerative disorder or 
has contributions from vascular disease remains con-
troversial. In the present study, VMR was lower in 
patients with mild-to-moderate AD than in age- and 
sex-matched control subjects. Several TCD studies have 
shown that the blood flow velocity is decreased in Lee ST, et al. Decreased Vasomotor Reactivity in Alzheimer’s Disease
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Figure 1. Difference in VMR values. VMR was significantly 
reduced in AD patients in the MCAs on both sides, being 
57.7±22.2 and 36.8±26.0 in control subjects and AD 
patients, respectively, on the right side, and 58.7±21.1
and 37.2±22.7 on the left side (*p<0.05 vs. control).
Figure 2. Correlation between MMSE score and VMR. 
Scatterplot shows no correlation between MMSE score 
and VMR both in the right-side (p=0.758) and left-side 
(p=0.324) MCAs.
AD,
18,19 and one study found an association between 
VMR and future cognitive decline in AD.
11 However, 
the present report is the first to compare VMR between 
AD patients and nondemented subjects. 
In the RSS study, VMR was reduced in subjects with 
cognitive decline but not in patients with clinical 
dementia.
10  In addition, the cerebral blood MFV was 
correlated with both the cognitive decline and the 
clinical dementia severity.
10 However, that study 
involved only 13 AD patients among 1730 subjects, 
which might have resulted in a lack of statistical power, 
and it was suggested that reduced VMR in AD was 
related to significant vascular comorbidity.
10 It has 
recently been reported that reduced cerebrovascular 
reactivity predicts cognitive decline in AD patients.
11 
However, that report presented no information on the 
level of VMR in the AD patients, and hence on whether 
VMR decreased with the disease progression.
11
In the present study, VMR but not the blood flow 
velocity was lower in AD patients than in the controls. 
This suggests that the pathologic changes of AD are 
more closely related to VMR than to the flow velocity 
itself. It is known that a reduced VMR is correlated 
with the severity of microangiopathy, which increases 
vascular resistance.
20,21 In addition, reduced VMR is 
representative of a reduced vasomotor reserve, which 
is prominent in hemodynamically significant stenosis 
or occlusion of the internal carotid artery.
10,20 Because cere-
brovascular CO2 reactivity is influenced by athero-
sclerosis through disturbance of the integrity and function 
of the arterial wall, a reduction in VMR to hypercapnia 
is indicative of cerebral small-vessel pathology.
10,20
Nevertheless, whether reduced VMR is correlated 
with decreased cerebral perfusion is not yet certain. 
Critical threshold cerebral hypoperfusion may result in 
changes to the capillaries, including basement membrane 
thickening, endothelial cell compression, degeneration of 
pericytes, and lumen distortion.
9 These changes can 
reduce the capacity of the arterioles to dilate in response 
to CO2 stimuli, which represents VMR. Consequently, 
reduced VMR is likely to be related to (or at least 
associated with) critical hypoperfusion. Direct measure-
ment of cerebral perfusion and metabolism using SPECT 
or PET will provide more information about the signi-
ficance of a reduced VMR.
It remains unclear whether the decreased perfusion 
reflects the diminished demand caused by advanced 
neurodegeneration, or whether cerebral hypoperfusion 
precedes and contributes to dementia and neurode-
generation. The decreased delivery of oxygen due to the Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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decreased cerebrovascular reserve can lead to hypoxia in 
vulnerable areas of the brain, such as watershed areas 
and the hippocampus,
10 and can negatively affect cog-
nitive function. In addition, any events that reduce 
cerebral blood flow and perfusion can trigger cerebral 
injury in patients with a reduced VMR.
We found no correlation between the MMSE score 
and VMR in the present study. In addition, VMR was 
not correlated with the grade of white-matter lesions. 
However, these results are not conclusive given the 
small number of patients in our study. Therefore, future 
studies should include a larger population of AD 
patients, and also evaluate cognitive function in more 
detail (i.e., using instruments additional to the MMSE). 
In addition, follow-up measurements of VMR and 
assessments of their correlation with the degree of 
cognitive decline are warranted.
Several methods have been used to measure VMR. 
The semiclosed rebreathing method as used in this 
study is easy to apply to and well tolerated by elderly 
demented patients, who may be uncooperative. The 
value of VMR measured by this method is comparable 
to that obtained by CO2-inhalation and breath-holding 
techniques.
17 In the present study, an adequate CO2 
retention of near 50 mmHg or more was obtained in all 
subjects. 
In conclusion, we have shown that VMR is reduced 
in patients with AD, which may be indicative of the 
microangiopathy of AD. Screening of cerebrovascular 
reserve by measuring VMR using TCD could represent 
a much-needed, reliable, safe, and cost-effective tech-
nique for patients at risk of dementia. Future studies 
should check the validity of these experimental and 
hypothesis-generating pilot results.
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